Geno is a 30 year veteran of the pharmaceutical and Life Sciences industry and is currently President and CEO of Elucida Oncology, a start-up biotechnology company developing novel C’Dot-Drug Conjugates for improved treatment of Cancer.
Prior to joining Elucida Oncology, Geno was President of Intrexon, a leader in synthetic biology, from June 2016to March 2017, and prior to Intrexon, Mr. Germano held multiple Executive roles at some of the world's largest and most innovative companies, including Pfizer, Johnson & Johnson and Wyeth. Mr. Germano led Pfizer's Global Innovative Pharmaceutical Business, cultivating a $14 billion operation and guiding the development of an extensive portfolio of products in the cardiovascular, immunology, metabolic disease, neuroscience and rare disease areas. Previously, he was President and General Manager of Pfizer's Specialty Care, Vaccines and Oncology business units.
Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., President of Global Pharmaceutical and Women's Healthcare Business and Executive Vice President of the Vaccines Business. He has served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee, and Chair of the International Committee. He served on the Advisory Board of the Healthcare Businesswomen's Association and was a Director of Zoetis (NYSE:ZTS) and a member of its Compensation Committee, Director of Bioverativ (NASDAC:BIVV), and member of its Nominating and Governance Committee, until it’s sale to Sanofi in March of 2018, and Director of The Medicines Company (NASDAQ:MDCO) and Chairman of its Compensation Committee, until it’s sale to Novartis in January 2019. He is currently a Director of Sage Therapeutics (NASDAQ:SAGE) and Chairman of its Nominating and Governance Committee, and of Precision Biosciences (NASDAQ:DTIL) and a member of its Audit Committee and Compensation Committee. Mr. Germano received his Bachelor of Science degree at the Albany College of Pharmacy and Health Sciences.
Speaking In
[Available On-Demand]
Elucida Oncology, Inc., is a privately-held biotechnology company focused on the development of…